Home / People / Dr Daniel Jenny

Dr Daniel Jenny, LL.M.

Partner

CMS von Erlach Poncet Ltd.
Dreikönigstrasse 7
P.O. Box
8022 Zurich
Switzerland
Languages German, English, French

Daniel Jenny specialises in M&A transactions, capital markets, corporate restructurings as well as general corporate and commercial matters (e.g. joint ventures, shareholders' agreements). He is active in various sectors, including Private Equity/Venture Capital, TMC and Life Science & Healthcare.

Besides his vast experience in a broad range of national and international M&A and private equity transactions, Daniel Jenny represents investors and startups in venture capital investments and financing rounds. He also has a broad experience in corporate restructurings, including distressed M&A (e.g. purchase of companies in insolvency proceedings). Further, he advises on corporate governance, in particular concerning questions on directors' liability. In his fields of expertise, Daniel Jenny often represents clients in corporate litigation such as post M&A, directors' liability or other corporate disputes (e.g. special audits or challenge of shareholders' resolutions).

After his traineeship with CMS and his clerkship with the District Court of Zurich, Daniel Jenny was admitted to the bar in 2007 and has since been working as a lawyer with CMS. He gained additional work experience as an international associate in a New York-based law firm and as legal counsel with an industrial multinational (Hilti AG). Daniel Jenny has authored various legal publications. His thesis "Means of Defence of Board Members in Directors' Liability Lawsuits", approved by the University of Zurich in 2012 (summa cum laude), was awarded with the Professor Walther Hug prize. Daniel Jenny has been constantly recommended in legal directories such as Chambers and Partners, The Legal 500 and IFLR1000.

more less

Sources describe Daniel Jenny as "calm under pressure, business-oriented, pragmatic and efficient."

Chambers and Partners, Corporate/M&A - Switzerland, Global, 2020

Daniel Jenny is an exceptionally smart and skilled lawyer. He is technically outstanding and at the same time commercial and pragmatic.

The Legal 500, Commercial, Corporate and M&A, Switzerland, 2020

"Strong communication, creative and open to involve other disciplines."

IFLR1000, Financial and corporate, Switzerland, 2019

Daniel Jenny is able to think through complex questions very quickly and give to the point, direct answers.

Chambers and Partners, Corporate/M&A, Switzerland, 2019

Daniel Jenny is recommended by clients as "rising star" in the area "Commercial, Corporate and M&A".

The Legal 500, Commercial, Corporate and M&A, Switzerland, 2018

Relevant experience

more less

Education

  • 2012 Doctorate, Dr. iur., summa cum laude, University of Zurich, Prof. Walther Hug Preis
  • 2010 Master of Laws, LL.M ,New York University School of Law, Half Tuition Dean's Graduate Award
  • 2007 Bar admission
  • 2004 Visiting Scholar, Max Planck Institute for Foreign and International Private Law, Hamburg
  • 2003 Law studies, lic. iur., magna cum laude, University of Zurich
more less

Memberships

  • Zurich Bar Association (ZAV)
  • Swiss Bar Association (SAV)
  • SECA
more less

Lectures list

  • Share Purchase Agreements: Latest Developments and Trends, Finanz und Wirtschaft Forum, Corporate Finance, Mergers & Acquisitions 2019, Business Transformation – the new Normal, 27 August 2019
  • Role of Board Members in M&A Transactions, Finanz und Wirtschaft Forum, Corporate Finance, Mergers & Acquisitions 2018, Shape your Business, 11 September 2018
  • Neue Finanzierungsformen: Crowdfunding und Initial Coin Offering (ICO), CMS M&A Breakfast, 15. Mai 2018
  • Unternehmenstransaktionen im rechtlichen und ökonomischen Kontext, Arten und Ablauf einer M&A Transaktion aus juristischer Sicht, Gastvorlesung an der HSG vom 25. April 2018
  • Abwehrmöglichkeiten von Verwaltungsratsmitgliedern gegen den Vorwurf der Pflichtverletzung, 9. EIZ-Tagung zur Verantwortlichkeit im Unternehmensrecht, 29. August 2017
  • Post-Closing M&A Disputes │ Rechtliche Aspekte, CMS M&A Breakfast, 10. Mai 2016
  • Überblick und Neues zur Business Judgment Rule, Aktuelle Entwicklungen in der aktienrechtlichen Verantwortlichkeit, CMS Lunch, 14. März 2013
  • Abwehrmöglichkeiten von Verwaltungsratsmitgliedern in Verantwortlichkeitsprozessen, Eine prozessuale Betrachtung, Institut für Rechtswissenschaft und Rechtspraxis, Universität St. Gallen, ZPO – Fallstricke und Chancen, 7. März 2013
more less

Feed

Show only
25 January 2021
Cor­por­ate Up­date: Swiss 2021 le­gis­lat­ive changes in­clude mod­ern­isa­tion...
After a tur­bu­lent and un­usu­al 2020 which saw nu­mer­ous short-term Cov­id-19-re­lated leg­al changes, vari­ous planned le­gis­lat­ive pro­jects (un­re­lated to the Cov­id-19-pan­dem­ic) entered in­to force as per 1 Janu­ary...
27 August 2020
CMS ad­vises Ever­bridge on the ac­quis­i­tion of Tech­wan SA
Ever­bridge has ac­quired all of the is­sued shares in Tech­wan SA. The base con­sid­er­a­tion was paid in part in cash and in part in newly is­sued shares of com­mon stock in Ever­bridge, Inc. With the ac­quis­i­tion...
02 July 2020
CMS ad­vises capiton/Cym­biQ on the ac­quis­i­tion of As­pec­tra AG
Cym­biQ Group AG, a port­fo­lio com­pany of Ger­many private equity in­vestor capiton, has ac­quired As­pec­tra AG, Zurich.As­pec­tra AG spe­cial­ises on man­aged host­ing ser­vices for crit­ic­al ap­plic­a­tions and of­fers...
26/06/2020
Apotal Group sells on­line phar­macy’s mail-or­der busi­ness and dia­betes arm...
Stut­tgart – Com­pany founder Heinz-Peter Fichter and oth­er share­hold­ers have sold the mail-or­der busi­ness of on­line phar­macy Apotal and its dia­betes di­vi­sion to the lis­ted Zur Rose Group of Switzer­land...
12 May 2020
CMS Ex­pert Guide to the leg­al as­pect for com­pany dir­ect­ors & CEOs
Even be­fore the COV­ID-19 glob­al pan­dem­ic, dir­ect­ors of com­pan­ies were un­der great­er scru­tiny than ever, with in­creas­ing con­cerns be­ing ex­pressed over gov­ernance and even the fun­da­ment­al pur­pose of com­mer­cial...
15 April 2020
New rank­ings from "The Leg­al 500" for CMS Switzer­land
New rank­ings from "The Leg­al 500" for CMS Switzer­land CMS Switzer­land is be­ing re­com­men­ded in 16 cat­egor­ies in this year's edi­tion of The Leg­al 500, pub­lished in April 2020. We are par­tic­u­larly pleased...
12 March 2020
Top-Rank­ings for CMS Switzer­land by Cham­bers and Part­ners
Top rank­ings for CMS Switzer­land by Cham­bers and Part­ners CMS Switzer­land is de­lighted to an­nounce that 14 law­yers across 10 prac­tice areas have been re­com­men­ded in the 2020 edi­tion of Cham­bers and...
27 November 2019
CMS ad­vised EMS-Group on the sale of EMS-PATVAG (s.r.o.)
CMS ad­vised EMS-Group on the sale of EMS-PATVAG (s.r.o.)  An in­ter­na­tion­al team of CMS Switzer­land and the Czech Re­pub­lic un­der the lead of Stefan Brunnsch­weiler (CMS Switzer­land) has ad­vised EMS-Group...
15 November 2019
CMS ad­vised ABB on the ac­quis­i­tion of Cas­santec Ltd
CMS ad­vised ABB on the ac­quis­i­tion of Cas­santec Ltd An in­ter­na­tion­al team of CMS Switzer­land and Ger­many un­der the lead of Stefan Brunnsch­weiler (CMS Switzer­land) has ad­vised ABB on the ac­quis­i­tion of...
20 September 2019
D&O Li­ab­il­ity and In­sur­ance – Part 1: Basis of Li­ab­il­ity and Avoid­ance...
Au­thors: Dr Daniel Jenny / Dr Clem­ens von Zedtwitz In­tro­duc­tion The max­im "Any­thing that can go wrong will go wrong" is es­pe­cially true of busi­ness where mis­takes can nev­er be fully avoided. Board mem­bers...
20 September 2019
D&O Li­ab­il­ity and In­sur­ance – Part 2: Ob­tain­ing ad­equate In­sur­ance Cov­er­age
Au­thors: Dr Daniel Jenny / Dr Clem­ens von Zedtwitz   In­tro­duc­tion The max­im that "Any­thing that can go wrong will go wrong" is es­pe­cially true of busi­ness where mis­takes can nev­er be fully avoided...
15 August 2019
Switzer­land re­vises trans­par­ency ob­lig­a­tions
Switzer­land re­vises trans­par­ency ob­lig­a­tions – Part 2: Swiss par­lia­ment in­tro­duces crim­in­al fines for vi­ol­a­tions Switzer­land re­vises trans­par­ency ob­lig­a­tions On 21 June 2019, the Swiss par­lia­ment...